Anagrelide

Active ingredient description

Anagrelide is an inhibitor of cyclic AMP phosphodiesterase III and suppress expression of transcription factors including GATA-1 and FOG-1 required for megakaryocytopoiesis, ultimately leading to reduced platelet production.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
L01XX35
Anagrelide
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX35

Medicines

Anagrelide is the active ingredient of these drugs:

Drug
Countries
AGRYLIN

Brazil Canada Hong Kong New Zealand Singapore

ANAGRELIDE

Austria

ATREMIA

Poland

GRALIDON

Estonia Lithuania

GRENALVON

Poland

MONBOC

Brazil

THROMBOREDUCTIN

Austria Lithuania Poland

XAGRID

Austria Cyprus Estonia Finland France

XERALID

Austria Germany

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
XAGRID Capsule
Summary of Product Characteristics (SPC)
AGRYLIN Capsule
Structured Product Labeling (SPL/PLR)
US

Structural formula

Graphic representation of the active ingredient's molecular structure

Molecular mass: 256.088 g/mol

External identifiers

CAS Substance: 68475-42-3
DrugBank Drug: DB00261
KEGG Drug: D07455
RxNorm Ingredient: 596724
SNOMED-CT Concept: 372561005
Anagrelide (substance)
UNII Identifier: K9X45X0051
ANAGRELIDE
 
Next: Usage >